WILMINGTON, Del. — Shareholders claim in a federal class action that directors of The Medicines Company made false and misleading statements to support its sale to Novartis for $85 per share or $9.7 billion.
Subscribe to our free newsletters
Our weekly newsletter Closing Arguments offers the latest about ongoing trials, major litigation and rulings in courthouses around the U.S. and the world, while the monthly Under the Lights dishes the legal dirt from Hollywood, sports, Big Tech and the arts.
Additional Reads
-
Court adviser signals uphill climb for Meta in EU antitrust data fight February 26, 2026 -
EU high court grounds airfreight cartel February 26, 2026
